There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mersana Therapeutics (MRSN – Research Report), ...

Stock analysts at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Mersana Therapeutics in a note issued to ...

Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Mersana Therapeutics in a ...

Q4 2024 Earnings Call Transcript March 3, 2025 Mersana Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.11 ...

Mersana Therapeutics Inc . (NASDAQ:MRSN) stock has reached a new 52-week low, trading at $0.56, as the biopharmaceutical company faces a challenging market environment. According to InvestingPro ...

CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of ...

Mersana Therapeutics Inc (NASDAQ:MRSN) is set to release its Q4 2024 earnings on March 3, 2025. The consensus estimate for Q4 ...

MERSANA THRPEUTIC ($MRSN) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of -$0.11 per share, beating estimates of -$0.16 by $0 ...

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...